US/UK/Canada

Share

Contacts

  • Morten Henneveld

    CEO


    +46 18 55 39 93

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin

    OssDsign AB (publ) announces that the interim report for Q3 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q3 2024 results will also be presented at an investor webcast today November 12th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q3-2024-2/or via the OssDsign website.     The third quarter in figures   · Net sales amounted to TSEK 35,728 (31,697). As all sales now derive from orthobiologics, which in the corresponding

    OssDsign has appointed Stephen Anderson as Vice President of Marketing

    OssDsign AB (publ.) today announced that the company has appointed Stephen Anderson as Vice President (VP) of Marketing and a member of the executive management team. The recruitment is a strategic step to increase the company’s presence in the U.S.Stephen Anderson has over 25 years of global experience in marketing, sales, and engineering in the medical device industry. He has held various senior roles, including Senior Vice President of Sales and Marketing at Sharp Fluidics, Vice President of Sales and Marketing at NeoSurgical, Senior Director of Marketing at Invuity, and Global Director

    OssDsign AB (publ) publishes Q2 2024 Interim Report

    Reaching milestone in orthobiologics salesOssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q2 2024 results will also be presented at an investor webcast today August 20th at 11:00 CET. The webcast can be accessed via the following link: www.finwire.tv/webcast/ossdsign/q2-2024/ or via the OssDsign website.    The second quarter in figures   · Net sales amounted to TSEK 29,737 (23,997), corresponding to a growth of 143%, or 139%

    Annual General Meeting held in OssDsign AB

    Today, the annual general meeting of 2024 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.ossdsign.com, and supplemented by a press release published on 24 June 2024).PRESS RELEASEOssDsign ABUppsala, 25 June, 2024  The annual general meeting resolved:  -        to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for

    Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign

    The board of directors of OssDsign AB, following discussions with a larger group of major shareholders, announces the withdrawal of the proposed incentive programs and the nomination committee’s revised proposal as regards election of and fees payable to board members ahead of the annual general meeting.PRESS RELEASEOssDsign ABUppsala, 24 June, 2024  On 24 May 2024, the notice to OssDsign’s annual general meeting, to be held on 25 June 2024 in Stockholm, was published. In the notice, two (2) different share related incentive programs were proposed for employees and contractors and

    5,000 patients treated with OssDsign Catalyst® in the U.S.

    Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.   “With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it's accelerating. This is a significant leap from the earlier announcements of

    NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB

    The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Tuesday 25 June 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company’s articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (se section Proxy collection below for more

    OssDsign AB (publ) publishes Q1 2024 interim report

    We have successfully entered a new era as a pure play orthobiologics companyOssDsign AB (publ) announces that the interim report for Q1 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q1 2024 results will also be presented at an investor webcast today May 14th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q1-2024/ 

    OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals

    Uppsala, Sweden, April 29 – OssDsign AB (publ.) today announces that the company has been awarded a new Veteran Affairs (VA) contract which covers approximately 100 additional VA orthopedic hospitals nationwide, giving OssDsign increased access to the important U.S. military market.The new contract is a continuation of OssDsign’s collaboration with Red One Medical, one of the most respected medical technology private sector representatives to the U.S. government that identifies medical innovations for the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD). The

    OssDsign awarded long-term agreement with Premier, Inc.

    Uppsala, Sweden, April 2 – OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing (GPO) agreement for Bone and Bone Substitute Implantable Products with Premier, Inc., a leading U.S. healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.Effective July 1, 2024, the agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for

    OssDsign appoints Tom Buckland as Chief Technical Officer

    OssDsign AB (publ.) today announces that the company’s current VP of Strategy, Business Development and Regulatory Affairs, Tom Buckland, has been appointed Chief Technical Officer (CTO). The promotion is a key part of the company’s change of direction into a pure-play orthobiologics company focusing exclusively on the U.S. Market.Tom Buckland, currently VP of Strategy, Business Development and Regulatory Affairs, will in his new role be responsible for Operations & Manufacturing, Research & Development as well as Quality Assurance and Regulatory Affairs.   “Since the Acquisition of

    OssDsign AB (publ) publishes year-end report 2023

    Exceptional sales growth for OssDsign Catalyst confirms the value of our strategy shiftOssDsign AB (publ) announces that the interim report for Q4 2023 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.   The Q4 2023 results will also be presented at an investor webcast today February 6th at 10:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/ossdsign-year-end-report-2023/ 

    12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research

    Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst."The publication of the outstanding clinical results in TOP FUSION is a crucial step in our process of establishing OssDsign Catalyst as a clinically proven

    OssDsign reports exceptional data from the clinical study TOP FUSION

    Uppsala, January 9, 2024. OssDsign AB (publ.) today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst.The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. They also confirm the previously reported best-in-

    OssDsign’s revenues for the fourth quarter of 2023 are expected to exceed market estimates

    OssDsign AB (publ.) today announces that the company expects its revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October – November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system.According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.   "The

    SEB Venture Capital has sold its holding in OssDsign

    Uppsala, November 30, 2023. OssDsign AB (publ) today announced that SEB Venture Capital has sold its entire holding of about 7.44 million shares, corresponding to approximately 7.6 % of the shares in OssDsign.“SEB Venture Capital has been a major shareholder in OssDsign during its development from a Swedish start-up as a cranial patient specific implant company to an international orthobiologics company with rapidly accelerating revenues. I am very pleased with the continued high interest from Swedish and international institutional investors to take part in the value creation we are

    OssDsign changes Certified Adviser to Carnegie Investment Bank AB (publ)

    OssDsign AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB.OssDsign has entered into an agreement with Carnegie Investment Bank AB regarding the position of Certified Adviser. Carnegie Investment Bank AB will take over as Certified Adviser as of today.   For further information, please contact: Morten Henneveld, CEO, OssDsign AB Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com   Certified Adviser The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)   About OssDsign

    OssDsign AB (publ) publishes Q3 2023 Interim Report

    A new era with OssDsign as a pure play orthobiologics companyOssDsign AB (publ) announces that the interim report for Q3 2023 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q3 2023 results will also be presented at an investor webcast today November 21st at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q3-2023/ or via the OssDsign website.     The third quarter in figures · Net sales amounted to TSEK 31,697 (17,496), which corresponds

    Extraordinary General Meeting held in OssDsign AB

    Today an extraordinary general meeting was held in OssDsign AB (publ) (the “Company”). Below is a summary of the resolutions passed at the general meeting (all in accordance with the proposals presented in the notice to attend the general meeting kept available at the Company’s website www.ossdsign.com).The extraordinary general meeting resolved to approve the board of directors’ resolution on issuance of new shares with deviation from the shareholders’ preferential rights. As communicated in the Company’s press releases from 26 September 2023, the Company’s board of directors had

    OssDsign Catalyst becomes universally available to all Military Treatment Facilities in the U.S. via ECAT

    OssDsign AB (publ.) today announces that the company’s nanosynthetic bone graft, OssDsign Catalyst has been included in the Department of Defense’s Military Health System’s electronic catalogue (ECAT), which means that the product is now universally available and can be ordered directly from any of the more than 50 Military Treatment Facilities in the U.S.The uptake of OssDsign Catalyst in ECAT has been mediated through the previously communicated collaboration with Red One Medical, a private-sector scout of medical innovation for the Department of Veterans Affairs (VA) and the Department

    Notice to attend the extraordinary general meeting in OssDsign AB

    The shareholders in OssDsign AB, reg. no. 556841-7546 (the “Company”), are hereby given notice to attend the extraordinary general meeting at 10:00 am on Monday 16 October 2023 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.Notice Shareholders wishing to participate at the meeting must: (i) be entered in the shareholders’ register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day which is Friday 6 October

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media